Bailard, Inc. Akero Therapeutics, Inc. Transaction History
Bailard, Inc.
- $3.8 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding AKRO
# of Institutions
190Shares Held
73.8MCall Options Held
241KPut Options Held
647K-
Wellington Management Group LLP Boston, MA7.9MShares$258 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X07.08MShares$232 Million0.11% of portfolio
-
Rtw Investments, LP New York, NY5.92MShares$194 Million2.71% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$183 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$171 Million4.29% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.52B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...